FAKTOR-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time Boerse Frankfurt Warrants 07:28:51 03/06/2024 pm IST | ||
| 6.65 EUR | -6.73% |
|
| 1 month | -45.41% | ||
| 3 months | -26.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 6.65 | -6.73% |
| 31/24/31 | 7.13 | -10.99% |
| 30/24/30 | 8.01 | +0.88% |
| 29/24/29 | 7.94 | +4.06% |
| 28/24/28 | 7.63 | +13.71% |
Real-time Boerse Frankfurt Warrants
Last update June 03, 2024 at 07:28 pm IST
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SU6UKF |
| ISIN | DE000SU6UKF6 |
| Date issued | 11/01/2024 |
| Strike | 420.9 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.14 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.3 € |
|---|---|
| Lowest since issue | 6.65 € |
| Spread | 0.04 € |
| Spread % | 0.56% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Certificates
- Certificat
